EICHOR
● Completed
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Condition: Head and Neck Cancer · Sponsor: Incyte Corporation
About this study
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (73)
| Pacific Cancer Medical Center | Anaheim, California, United States | — |
| UC Davis Comprehensive Cancer Center | Sacramento, California, United States | — |
| St. Joseph Heritage Healthcare | Santa Rosa, California, United States | — |
| University of Colorado Cancer Center | Aurora, Colorado, United States | — |
| Yale Cancer Center | New Haven, Connecticut, United States | — |
| Northwest Georgia Oncology Centers PC | Douglasville, Georgia, United States | — |
| U of Kansas Cancer Center | Westwood, Kansas, United States | — |
| Baptist Health | Louisville, Kentucky, United States | — |
| St. Vincent Healthcare Cancer Ctr | Billings, Montana, United States | — |
| New Mexico Cancer Care Alliance | Albuquerque, New Mexico, United States | — |
| Oklahoma Cancer Specialists and Research | Tulsa, Oklahoma, United States | — |
| Providence Portland Med Center | Portland, Oregon, United States | — |
+ 61 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03358472